- Myovant Sciences press release (NYSE:MYOV): Q3 GAAP EPS of -$0.56 beats by $0.08.
- Revenue of $100.23M (+84.1% Y/Y) misses by $2.13M.
- Cash, cash equivalents, marketable securities, and amounts available under the Sumitomo Pharma Loan Agreement totaled $315.7 million in the aggregate as of December 31, 2022, and consisted of $274.4 million of cash, cash equivalents, and marketable securities and $41.3 million of available borrowing capacity under the Sumitomo Pharma Loan Agreement.